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Introduction
The 2016 UNGASS on drugs was hailed as an opportu-
nity ‘to conduct a wide-ranging and open debate that 
considers all options’.1 Although the UNGASS process 
had some challenges, it was nonetheless a critical 
moment for global drug policy reform.2 In June 2017, 
the UN Secretary General welcomed the UNGASS 
Outcome Document as a ‘forward-looking blueprint 
for action’ and called on governments to ‘honour the 
unanimous commitments’ made.3 
The next opportunity to build on the important progress 
made at the UNGASS is the ‘High Level Ministerial 
Segment’ of the 62nd Session of the Commission on 
Narcotic Drugs (CND), as agreed in CND Resolution 
60/1: ‘Preparations for the sixty-second session of 
the Commission on Narcotic Drugs in 2019’.4 2019 
is the target date established in the 2009 Political 
Declaration and Plan of Action5 ‘for States to eliminate 
or reduce significantly and measurably’ illicit drug 
supply and demand, the diversion and trafficking of 
precursors and money laundering.6 Evidence from the 
UN itself shows that these targets are unachievable, 
and in the 2017 World Drug Report, the UNODC states 
clearly that the ‘drug market is thriving’.7   
The 2019 moment is fast approaching, and the 
modalities for the event will likely be finalised at the 
61st Session of the CND, which will be held from 12th 
to 16th March 2018. In this context, it is critical that a 
clear process be established to: 
• Review progress made in light of the 2019 target 
date set in paragraph 36 of the 2009 Political 
Declaration, including main trends, achievements 
and gaps
• Conduct a genuine debate on the state of global 
drug policy, considering ‘all options’, and involving 
all relevant stakeholders
• Delineate a roadmap for 2019 and beyond to 
effectively operationalise the recommendations 
included in the UNGASS Outcome Document.
To inform these deliberations, this IDPC advocacy note 
outlines some of the key issues and possible options 
for 2019.8
An honest review of progress (or 
lack thereof) made since 2009
In CND Resolution 60/1, member states decided that 
the Ministerial Segment will be the moment ‘to take 
stock of the implementation of the commitments 
made to jointly address and counter the world drug 
problem, in particular in light of the 2019 target 
date’. At present, the procedure for a review of pro-
gress towards these targets remains unclear. How-
ever it is imperative that the evaluation process be 
transparent, scientific, evidence-based and inclusive 
to honestly reflect on the progress, or lack thereof, 
that has been made over the past 10 years. A genu-
ine review process will also allow member states to 
reflect on the ongoing validity and utility of targets 
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‘It is vital that we examine the effectiveness of the 
war-on-drugs approach and its consequences for 
human rights. Despite the risks and challenges 
inherent in tackling this global problem, I hope 
and believe we are on the right path, and that, 
together, we can implement a coordinated, 
balanced and comprehensive approach that 
leads to sustainable solutions. This would be 
the best possible way to implement the Special 
Session’s recommendations and to have a 
positive impact on the lives of millions of people 
around the world’.9
Antonio Guterres, UN Secretary General 
2focused on eliminating the illicit drug market and 
the establishment of a ‘society free of drug abuse’. 
Building on the 2009 process
At the 1998 UNGASS, member states agreed on a 
Political Declaration that aimed for ‘significant and 
measurable results in the field of demand reduction’ 
and ‘eliminating or reducing significantly’ illicit crop 
cultivation by 2008.14 When this target year came 
around, proposals for convening another UNGASS 
were dismissed. Instead, ‘to allow additional time 
for conducting an objective, scientific, balanced and 
transparent global assessment’,15 member states de-
cided to divide the review process into three stages: 
1) a thematic debate at the 2008 CND to discuss the 
outcomes of an assessment by the UNODC on the 
global progress against the 1998 Political Declaration; 
2) a subsequent ‘period of reflection’ during which 
five intergovernmental expert working groups elabo-
rated a number of recommendations;16,17 and 3) the 
negotiation of the new Political Declaration and Plan 
of Action, adopted at a High-Level Meeting in Vien-
na in March 2009, structured under three pillars: de-
mand reduction, supply reduction and international 
cooperation. Civil society fed into the process through 
a parallel series of consultations and meetings result-
ing in the ‘Beyond 2008 Declaration’.18 This process 
could be a useful model for member states to con-
sider – albeit for refinement rather than replication. 
Evaluating progress made since 2009
The UN drug control system has repeatedly set 
unrealistic goals to significantly reduce and even 
eradicate the global drug market. This has left member 
states with a difficult dilemma – how to emphasize the 
ongoing priority of an escalating world drug problem, 
without openly acknowledging the inherent failure and 
ineffectiveness of existing policies and approaches. 
This inability to provide an honest critique hampers 
progress and the exploration of urgently needed new 
approaches. 
2019 therefore constitutes a crucial opportunity for a 
long-overdue evaluation to explore progress made (or 
lack thereof) since the adoption of the 2009 Political 
Declaration. This should provide an honest and objective 
assessment of the failures of global drug control and 
its negative impacts on health, security, human rights, 
development and poverty; an assessment that failed to 
materialise at the 2014 mid-term review and the 2016 
UNGASS. This review would go hand-in-hand with the 
UNODC’s current efforts to update the Annual Report 
Box 1 Establishing new targets and indicators for the next decade 
As the 2009 goals and targets will expire in 2019, 
the High Level Ministerial Segment presents a key 
opportunity to move away from the targets in-
cluded in the 2009 Political Declaration and Plan 
of Action, and to consider instead new indicators 
to evaluate progress in global drug control for the 
next decade. The ongoing work to improve the 
‘quality and effectiveness’10 of the ARQ11 is com-
plementary to this process – as improving data 
collection and analysis is4 crucial to be able to ad-
equately monitor progress and impact. A number 
of NGOs have been working towards identifying 
more measurable, realistic and relevant indicators 
for the past few years, and are actively contribut-
ing to this discussion.12
The main objective for this review is threefold. 
Firstly is the need to move away from process in-
dicators (i.e. activities such as numbers of arrests, 
seizures and hectares of crops eradicated) and con-
sider outcome indicators (i.e. impacts on health, 
human rights, levels of corruption, violence and 
impunity). Process indicators are inherently flawed 
for a number of reasons, in particular because they 
do not measure the effects of interventions on 
either the scale or diversification of drug markets, 
or on the people and communities most affected.13
Secondly, some of the current imprecise, unreal-
istic and misconceived indicators (e.g. achieving a 
significant reduction in demand and supply) should 
be disregarded, in order to focus on others which 
are realistic, measurable and relevant to assess pro-
gress made. 
And thirdly, the updated ARQ should incorporate the 
new aspects of global drug control enshrined in the 
UNGASS Outcome Document, in particular in the ar-
eas of human rights, availability of controlled medi-
cines, improved access to health services and better 
health outcomes, and the implementation of devel-
opment programmes in areas affected by supply-side 
activities to reduce the risk factors of engagement in 
illicit economies. This will require embedding these 
new metrics and indicators in the broader frame-
work of the Sustainable Development Goals (SDGs), 
especially SDG 1 (No poverty), 3 (Good health and 
well being), 5 (Gender equality), 8 (Decent work and 
economic growth), 10 (Reduced equalities) and 16 
(Peace, justice and strong institutions).
3Questionnaire (ARQ), in order to better reflect the new 
priority areas within the UNGASS Outcome Document 
(see Box 1). However, the current proposal by the CND 
Chair to merely rely on the fourth biennial report of the 
UNODC Executive Director is not sufficient to ensure a 
truly comprehensive and inclusive evaluation process.19 
There is a long tradition of evaluation at the UN. Within 
the UNODC itself, an Independent Evaluation Unit 
(IEU) is mandated to evaluate the ‘implementation, 
performance and impact’ of UNODC’s programmes.20 
It is therefore not unreasonable for the UNODC to 
involve the IEU in a cross UN-agency process – perhaps 
in the form of a UN inter-agency working group tasked 
with conducting an independent, transparent and 
participatory evaluation of global drug control since 
2009. This assessment would measure any progress 
towards the goals set forth in the 2009 Political 
Declaration and Plan of Action, while also taking into 
consideration the additional aspects covered in the 
UNGASS Outcome Document, especially in the areas of 
human rights, health and development.
To ensure that the process is truly participatory, the 
UN inter-agency working group should call for inputs 
from member states, UN agencies and civil society 
– using a model similar to the pre-UNGASS call for 
contributions,21 or that routinely used by the Office of 
the High Commissioner on Human Rights when drafting 
its reports on key thematic areas.22 These submissions 
should be considered seriously and duly incorporated 
into the review process – and not be merely set aside 
as has been the case during the UNGASS.23 The final 
report should form the basis of discussions on the 
review of the 2009 Political Declaration at the 2019 
High Level Ministerial Segment. 
Deciding on the outcome of 
the 2019 High Level Ministerial 
Segment
 
Building upon the UNGASS Outcome 
Document
The UNGASS Outcome Document represents the most 
recent global consensus on drugs and a blueprint for 
action going forward. It should therefore not be side-
lined in 2019 for the following reasons:
• Its seven-chapter structure (covering health, ac-
cess to medicines, supply reduction, human rights, 
evolving trends and realities, international cooper-
ation, and development) is a significant improve-
ment on the three pillars of the 2009 Political Dec-
laration (demand reduction, supply reduction and 
international cooperation/money laundering). This 
new structure should be maintained for future UN 
drug policy documents and debates as it better 
links the cross-cutting nature of the drug control 
objective to protect the health and welfare of hu-
mankind, with the key priorities of the UN system – 
human rights, peace, humansecurity, development 
– and the SDGs. 
• The language from 2016 is an important improve-
ment on both 200925 and 201426 in the areas of 
human rights (in particular proportionate sentenc-
ing, due process, legal guarantees, ending impunity 
as well as ending torture, cruel or inhuman treat-
ment, etc.), gender sensitivity, development (with 
several references to the SDGs), and health (with 
the recognition of overdose prevention measures 
and other harm reduction interventions).27 All ef-
forts should be made to consolidate these gains in 
2019.
• The drug market, and the world more broadly, has 
changed significantly since 2009 – in particular the 
emergence of online drug markets and new psy-
choactive substances. All these aspects are better 
addressed in the UNGASS Outcome Document 
than in previous high-level declarations on drugs.
Operationalising the UNGASS Outcome 
Document
Based on negotiations in Vienna so far, and on the 
CND Chair’s background paper, member states appear 
to agree that there is ‘no need to negotiate a new pol-
icy document’, and that the 2019 event should focus 
on implementation of commitments made to date.28 
Given that UNGASS Outcome Document represents 
the most recent consensus, it would be expedient to 
focus on the operationalisation of its recommenda-
tions as well as taking into account any new indicators 
agreed through the ongoing data-collection improve-
ment work (see Box 1). 
‘UNGASS was a ground-breaking moment 
that provided a detailed and forward-looking 
blueprint for action. Together, we must honour 
the unanimous commitments made to reduce 
drug abuse, illicit trafficking and the harm that 
drugs cause, and to ensure that our approach 
promotes equality, human rights, sustainable 
development, and greater peace and security’.24
Antonio Guterres, UN Secretary General 
4In terms of format for an outcome, the CND Chair’s 
background paper proposes a Chair’s summary com-
bined with a procedural resolution. We welcome this 
proposal, provided that the Chair’s summary consists 
of a detailed proceedings document of the 2019 High 
Level Ministerial Segment, that adequately reflects 
the breadth of discussions and captures any disagree-
ments at the meeting, without forcing global consen-
sus – given the current political tensions between 
member states on many drug-related issues. Indeed, 
in both 2009 and 2016, any language considered as 
‘controversial’ was quickly filtered out, watered down 
or ignored as a result of in the consensus-based ne-
gotiations in Vienna.34 Alternatively, a report that pic-
tures different perspectives and scenarios for 2020-
2030 may also have merits, using a methodology 
similar to the one successfully used by the Organiza-
tion of American States in 2013.35 The procedural res-
olution should focus on clear actions for operational-
ising the UNGASS Outcome Document, in the form of 
a ‘roadmap’ for the next decade, establishing review 
dates (mid-term in 2024 and final review in 2029) to 
bring this process into line with 2030 Agenda for Sus-
tainable Development.36




A wide-ranging and open debate that 
considers all options 
The 2019 process needs to be open and transparent to 
allow for genuine debate. Instead of simply replicating 
the recent past, the process should focus on practical 
recommendations reflecting the divergence of views 
and the ongoing exploration of new approaches to 
address drug-related problems more effectively and 
coherently in the coming decade. 
The period from March 2018 to March 2019 should 
therefore build on the CND ‘inter-sessional’ meet-
ings between member states that have taken place in 
Vienna over the last two year focused on the seven 
themes of the UNGASS Outcome Document.38 This 
‘At the special session, the General Assembly laid 
the groundwork for the 10-year review of the 
Political Declaration and Plan of Action of 2009 
relating to the world drug problem, the main 
policy document guiding international action in 
this area. I look forward to an inclusive dialogue 
that is open to new ideas and approaches in the 
lead-up to that review’.37
Antonio Guterres, UN Secretary General 
Box 2 Ensuring a long-overdue discussion on cannabis polic 
In 2004, in General Assembly Resolution 59/160, 
member states requested that the UNODC prepare 
a global survey of cannabis,29 which resulted in a 
special chapter in the 2006 World Drug Report, en-
titled ‘Cannabis: Why we should care’.30 In the re-
port, the UNODC stated that ‘[t]he global commu-
nity is confused about cannabis’, and that ‘[c]oming 
to terms with cannabis is important because it is, 
by quite a wide margin, the world’s most popular 
illicit drug’.31 It further recognised that ‘much of the 
early material on cannabis is now considered in-
accurate, and that a series of studies in a range of 
countries have exonerated cannabis of many of the 
charges levelled against it’.32 It went on to note that 
‘[m]edical use of the active ingredients, if not the 
plant itself, is championed by respected profession-
als’. The report acknowledged that supply reduction 
is impossible given the potential to grow the plant 
anywhere and that all past attempts to control avail-
ability had failed. In its final conclusion, the report 
already raised the key issue concerning cannabis to-
day, 10 years ahead of the 2016 UNGASS: 
‘The world has failed to come to terms with 
cannabis as a drug. In some countries, canna-
bis use and trafficking are taken very seriously, 
while in others, they are virtually ignored. This 
incongruity undermines the credibility of the 
international system, and the time for resolving 
global ambivalence on the issue is long overdue. 
Either the gap between the letter and spirit of 
the Single Convention, so manifest with canna-
bis, needs to be bridged, or parties to the Con-
vention need to discuss redefining the status of 
cannabis’ 33 
However, the issue of cannabis was not discussed 
at the 2016 UNGASS, despite the fact that some 
jurisdictions had already legally regulated the sub-
stance and others announced they would be doing 
so. The 2019 High Level Ministerial Segment is a 
critical juncture to take up UNODC’s 2006 recom-
mendation and ‘discuss redefining the status of 
cannabis’.
5process could now evolve into a series of expert group 
meetings based on the seven UNGASS themes, with 
clear recommendations and actions focused on the 
operationalisation of the Outcome Document – and 
taking into account progress made on its implementa-
tion since its adoption in April 2016. 
The expert group recommendations should not rely 
on consensus in order to acknowledge and respect 
differing perspectives on drug policy, and should con-
sider all options, including those that may be outside 
of the scope of the international drug control con-
ventions. For example, the undeniable policy trend 
towards cannabis regulation in a number of countries 
was the elephant in the room throughout the UN-
GASS process (see Box 2) and a more open debate is 
required on how to deal with the tensions that such 
reforms create with the treaty regime, also taking into 
account the cannabis review process initiated by the 
WHO Expert Committee on Drug Dependence.39
To ensure inclusive discussions, the process should 
also ensure that all relevant UN entities, civil society, 
academia and affected populations, as well as all UN 
member states, are able to participate. 
Civil society participation
The strong presence of civil society40 in the debates 
prior to, during and post-UNGASS should be protect-
ed and consolidated for the 2019 process. Below are 
some suggestions to ensure meaningful civil society 
engagement in the 2019 process:
• Recognition, support and funding for the Civil So-
ciety Task Force in the leadup to 2019
• An online civil society consultation to provide 
inputs into the three broad mandates set forth 
above – facilitated by the Civil Society Task Force 
• Open calls for, and transparent selection of, civil 
society speakers for upcoming CND intersession-
als and other official meetings held in preparation 
for the High Level Ministerial Segment
• The organisation of a 2-day consultation in Vienna 
six months before the 2019 Ministerial Segment 
(September-October 2018) during which priorities 
and best practices will be identified – followed by 
a 1-day dialogue between civil society and mem-
ber states
• The organisation of a half-day civil society hearing 
in New York two months before the 2019 Minis-
terial Segment to keep the General Assembly in-
formed of the process, and foster exchange of in-
formation and expertise between civil society, UN 
agencies and member states
• The organisation of a civil society hearing the day 
before the 2019 Ministerial Segment
• The inclusion of civil society speakers in the panels 
of roundtables and plenary sessions of the 2019 
Ministerial Segment, as well as the option for a 
number of civil society speakers to make interven-
tions from the floor
• The preparation of a civil society contribution to 
be presented, and recognised, as an official docu-
ment of the 2019 High Level Ministerial Segment.




The gains that were made both during and since the 
UNGASS in terms of engaging other UN agencies42 need 
to be structurally built in for the 2019 process and be-
yond. The fact that the CND has been given a leading 
role on drug policy matters does not mean it holds a 
monopoly. Both the UN General Assembly43 and the 
CND44 call upon other UN agencies to engage in rele-
vant drug policy issues, to ‘identify operational recom-
mendations that fall within their areas of specializa-
tion’ and to implement them in coordination with the 
UNODC, the INCB and the WHO. The General Assembly 
has further invited the UNODC to ‘increase efforts to 
pursue joint initiatives at the policy and programmatic 
levels with other relevant UN agencies’ and to report 
to the CND on its progress.  The memorandum of un-
derstanding signed between the WHO and UNODC in 
2017 is a welcome development that strengthens col-
laboration between the two agencies and gives greater 
prominence to public health in UN drug control. 
Coordination efforts have already begun in New York 
and Geneva, with the support and encouragement of 
member states.45 In addition, as the mandates of other 
branches of the UN system very much intersect with 
drug policy, close coordination is a pre-requisite for a 
balanced and comprehensive approach, especially in 
the broader framework of the SDGs. Indeed, in 2017 
there has been increased attention given to drug pol-
icy within other UN settings such as the World Health 
Assembly46 and the Human Rights Council.47
For 2019, progress on UN coordination requires es-
tablishing:
• Clear criteria and transparency about UN system-
wide coherence and inter-agency collaboration
• A preparatory committee that represents all rele-
‘We are here to affirm the existential commitment 
of the whole UN system to ensure that the central 
focus of all our policies is the advancement of 
human dignity, equality and rights’.41
Antonio Guterres, UN Secretary General 
6vant UN agencies
• Opportunities for representatives of all relevant 
UN agencies to engage in the review process and 
the 2019 event (including as keynote speakers in 
panel discussions and roundtables)
• The appointment of a Special Advisor, or a similar 
mechanism, by the UN Secretary General to facil-
itate the involvement of the whole UN system in 
the 2019 process.
Member states’ participation
The annual drugs ‘omnibus’ resolution recently adopt-
ed by the Third Committee48 encourages all member 
states to actively participate in the discussions leading 
up to the 2019 Ministerial Segment in order to ‘foster 
an in-depth exchange of information and expertise on 
efforts, achievements, challenges and best practices 
to address and counter the world drug problem’.49 
Mechanisms should be in place to facilitate this active 
participation, particularly among smaller member 
states and others which do not have a permanent rep-
resentation in Vienna. In addition to regular UNODC 
briefings which serve to inform member states on de-
velopments in the process, other mechanisms should 
include formal consultations, hearings and roundtable 
discussions held in Vienna, New York and Geneva with 
member states, the CND Chair, as well as all relevant 
UN agencies and civil society. Close compulsory drug 
detention and rehabilitation centres and implement 
voluntary, evidence-informed and rights-based health 
and social services in the community.
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